• Galapagos NV GLPG.OQ reported quarterly adjusted earnings of €11.87​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 38 cents. The mean expectation of four analysts for the quarter was for a loss of €1.31 per share. Wall Street expected results to range from -79 cents to 9 cents per share.

• Revenue rose 1,101.5% to €6.48 million from a year ago; analysts expected €9.92 million.

• Galapagos NV's reported EPS for the quarter was €11.87​.

• The company reported quarterly net income of €14.49 million.

• Galapagos NV shares had fallen by 4.0% this quarter and lost 11.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 422.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Galapagos NV is $33.00, about 12.7% above its last closing price of $28.81

This summary was machine generated from LSEG data May 7 at 07:29 a.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)